As of June 2025, Brazil led the ranking of Latin American countries with most clinical trials, with more than ****** studies. Mexico ranked second, with over ***** clinical trials. As of the beginning of that year, the phase with the highest number of clinical trials in Brazil was phase 3.

Latin America Healthcare Contract Research Organization market will be USD 2241.31 million in 2024 and is estimated to grow at a compound annual growth rate (CAGR) of 7.3% from 2024 to 2031.The market is foreseen to reach USD 4045.4 million by 2031 owing to increasing demand for clinical trials and regulatory compliance expertise

Latin America's Biologics Drug Development market will be USD 377.56 million in 2024 and is estimated to grow at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031. The market is foreseen to reach USD 708.4 million by 2031 due to increasing prevalence of chronic diseases.

Global AI in Clinical Trials is segmented by Application (Oncology trials, Rare disease studies, Phase I–III trials, Real-world evidence, Protocol design), Type (AI for patient recruitment, Predictive trial analytics, eCRF automation, Virtual monitoring, Trial simulation) and Geography(North America, LATAM, West Europe, Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA)

Latin America's Pharmaceutical CXO market will be USD XX million in 2024 and is estimated to grow at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2031. The market is foreseen to reach USD XX million by 2031 due to its attractive destination for clinical trials due to its diverse patient population, which offers a broad spectrum of genetic backgrounds and health conditions.

In 2023, Brazil was by far the Latin American country with the highest pharmaceutical market value, amounting to around **** billion U.S. dollars. Mexico ranked second, with a pharma market value of approximately **** billion U.S. dollars. As a whole, Latin America accounted for about *** percent of the global 2023 pharmaceutical market revenue. An industry driven by importsBrazil produced more than ** billion Brazilian reals worth of pharmaceutical products in 2020. Despite its significant role in the national economy, the pharmaceutical industry in this South American country relies mostly on imports. In 2021, Brazil had pharmaceutical imports for about ** billion U.S. dollars in 2021. Meanwhile, Brazil’s pharma exports have declined from **** billion U.S. dollars in 2014 to **** billion U.S. dollars in 2023. ACHE Laboratorios – a national market leaderDespite U.S companies such as Pfizer leading the global pharmaceutical industry, in Brazil Aché Laboratorios Farmacéuticos S.A. - a prominent 100-percent Brazilian pharmaceutical corporation – ranks first in the segment, with a revenue of over **** billion Brazilian reals in 2021. Focusing mostly on the production and sales of prescription drugs, the company invested more than **** billion reals in research, development, and innovation in 2018.

Latin America CAR T-Cell Therapy Market growth is driven by increasing investment in biotech, expanding clinical trial networks, and government initiatives supporting cell therapy innovation in countries like China, Japan, and South Korea.

The global market size of Myeloproliferative Disorders Clinical Trials is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024.
Global Myeloproliferative Disorders Clinical Trials Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Myeloproliferative Disorders Clinical Trials industry. The key insights of the report:
1.The report provides key statistics on the market status of the Myeloproliferative Disorders Clinical Trials manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
2.The report provides a basic overview of the industry including its definition, applications and manufacturing technology.
3.The report presents the company profile, product specifications, capacity, production value, and 2013-2018 market shares for key vendors.
4.The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.
5.The report estimates 2019-2024 market development trends of Myeloproliferative Disorders Clinical Trials industry.
6.Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out
7.The report makes some important proposals for a new project of Myeloproliferative Disorders Clinical Trials Industry before evaluating its feasibility.
There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.
For competitor segment, the report includes global key players of Myeloproliferative Disorders Clinical Trials as well as some small players. At least 9 companies are included:
* Bristol-Myers Squibb
* AstraZeneca
* Eli Lilly
* Roche
* Merck
* Novartis
For complete companies list, please ask for sample pages.
The information for each competitor includes:
* Company Profile
* Main Business Information
* SWOT Analysis
* Sales, Revenue, Price and Gross Margin
* Market Share

For product type segment, this report listed main product type of Myeloproliferative Disorders Clinical Trials market
* Product Type I
* Product Type II
* Product Type III

For end use/application segment, this report focuses on the status and outlook for key applications. End users sre also listed.
* Application I
* Application II
* Application III

For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented from 2013 to 2023. This report covers following regions:
* North America
* South America
* Asia & Pacific
* Europe
* MEA (Middle East and Africa)
The key countries in each region are taken into consideration as well, such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.

Reasons to Purchase this Report:
* Analyzing the outlook of the market with the recent trends and SWOT analysis
* Market dynamics scenario, along with growth opportunities of the market in the years to come
* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects
* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
* Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
* 1-year analyst support, along with the data support in excel format.
We also can offer customized report to fulfill special requirements of our clients. Regional and Countries report can be provided as well.

Brazil, the most populated country and the economy with the highest GDP in Latin America, had the largest market research revenue in the region in 2022. Out of all the Latin American and Caribbean countries included in the study, Brazil ranked first, with a market research revenue of *** million U.S. dollars, followed by Mexico, with *** million U.S. dollars.

The Latin American melanoma diagnostics and therapeutics market is experiencing robust growth, projected to reach a significant size by 2033. A Compound Annual Growth Rate (CAGR) of 13.80% from 2025 to 2033 indicates substantial market expansion driven by several key factors. Increasing melanoma incidence rates across the region, coupled with rising awareness and improved diagnostic capabilities, are fueling demand for advanced dermatoscopy devices and biopsy techniques. The growing adoption of targeted therapies and immunotherapies, offering improved treatment outcomes and patient survival rates, further contributes to market growth. Brazil, Argentina, and Mexico are the leading markets within Latin America, reflecting higher healthcare expenditure and a greater concentration of specialized medical facilities. However, challenges remain, including limited healthcare infrastructure in certain regions, high treatment costs restricting access for a large segment of the population, and a shortage of skilled dermatologists. Despite these restraints, the market's positive trajectory is expected to continue, driven by technological advancements, increased investment in healthcare infrastructure, and government initiatives aimed at improving cancer care. The market segmentation reveals significant opportunities within both diagnostics and therapeutics. The diagnostics segment benefits from the growing adoption of non-invasive techniques like dermatoscopy, while the therapeutics segment is propelled by the increasing use of innovative treatments such as immunotherapy and targeted therapies which offer personalized medicine approaches. Key players such as Abbott Diagnostics, Amgen, Roche, and Pfizer are actively involved in developing and marketing advanced melanoma diagnostic tools and therapeutic solutions within the Latin American market. Their market leadership is expected to drive further innovation and market penetration in the coming years. Competition is likely to intensify with the emergence of smaller, specialized companies offering niche solutions. Future growth will be shaped by factors such as ongoing clinical trials, technological advancements, and regulatory approvals for novel therapies. Recent developments include: In November 2022, Medison Pharma announced the addition of South and Central America and the Caribbean markets, to its multi-territorial agreement with Immunocore Holdings plc, a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer like melanoma, infection and autoimmune disease., In April 2021, Melanoma Research Alliance announced that it is supporting creative partnerships between researchers, for example, a multi-national team of scientists in Mexico, Brazil, and the United Kingdom focused on unraveling the ways in which acral melanoma spreads throughout the body.. Key drivers for this market are: Increasing Incidences of Melanoma Cases, Advancements in Diagnosis and Treatments and Rising Government Initiatives. Potential restraints include: Increasing Incidences of Melanoma Cases, Advancements in Diagnosis and Treatments and Rising Government Initiatives. Notable trends are: Biological Therapy is Expected to Witness High Growth Over the Forecast Period.

Global Clinical Data Management Systems (CDMS) is segmented by Application (Clinical Trials, Medical Research, Data Security), Type (IT Services, Healthcare Solutions, Data Management) and Geography(North America, LATAM, West Europe, Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA)

Global Drug Discovery & Development Services is segmented by Application (Drug discovery, Clinical trials, Toxicology studies, Regulatory compliance, Contract research), Type (Preclinical, Clinical trial management, Toxicology, Regulatory, Bioinformatics) and Geography(North America, LATAM, West Europe, Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA)

The South and Central American Oil Country Tubular Goods (OCTG) market, valued at approximately $2.5 billion in 2025, is projected to experience robust growth, exhibiting a Compound Annual Growth Rate (CAGR) exceeding 4.5% from 2025 to 2033. This expansion is primarily driven by increasing oil and gas exploration and production activities across the region, particularly in Brazil and Argentina. Significant investments in infrastructure development and the ongoing expansion of existing oil fields are key catalysts. Furthermore, the rising demand for higher-grade OCTGs, reflecting a focus on enhanced drilling efficiency and well integrity, fuels market growth. The seamless OCTG segment holds a larger market share compared to Electric Resistance Welded (ERW) due to its superior strength and durability, particularly in challenging geological conditions. However, the market faces challenges including fluctuating oil prices, political and economic instability in certain countries, and potential supply chain disruptions. Despite these headwinds, the long-term outlook remains positive, driven by continued investments in the energy sector and the region's abundant hydrocarbon resources. The regional distribution of the market is skewed towards Brazil, which accounts for the largest share due to its considerable oil production capacity and extensive upstream investments. Argentina and Venezuela also contribute significantly, although their market shares may fluctuate depending on political and economic conditions. The "Rest of South and Central America" segment shows promising, albeit slower, growth potential, primarily driven by exploration activities in less-developed areas and increased investment from international players. Key players like ArcelorMittal SA, Tenaris SA, and Vallourec SA are strategically positioning themselves within the region, leveraging their technological capabilities and established supply chains to capture market share. The market's segmentation by manufacturing process (seamless vs. ERW) and grade (premium vs. API) allows companies to tailor their offerings to specific client requirements and maximize their market penetration. The ongoing trend toward utilizing advanced materials and technologies will continue to shape the competitive landscape, requiring manufacturers to invest in research and development to maintain their market position. Recent developments include: In November 2022, Vallourec SA, a multinational manufacturing company, planned to start a new business in Brazil. The new business will mainly focus on manufacturing 18 5/8" OCTG pipes., In June 2022, Energia Argentina and Tenaris SA, a global manufacturer and supplier of OCTG products, signed an agreement to supply welded and seamless pipes for the Presidente Nestor Kirchner Gas construction Pipeline (GPNK) in Argentina. Tenaris mills in Buenos Aires, Valentín Alsina, will start the operations to supply welded pipes for the GPNK.. Notable trends are: Premium Grade Segment is Expected to Witness Significant Demand.

Global Veterinary Cro And Cdmo is segmented by Application (Veterinary Medicine, Drug Development, Research, Clinical Trials, Regulatory Compliance, Quality Control, Animal Health), Type (Clinical Research, Regulatory Services, Manufacturing, Analytical Services, Preclinical Services, Consulting, Quality Assurance, Data Management, Project Management, Safety Assessments) and Geography(North America, LATAM, West Europe, Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA)

The Latin American country with the most significant information technology (IT) market in 2022 was Brazil, totaling ** billion U.S. dollars. Mexico ranked second, with an IT market value worth ** billion U.S. dollars, while Peru's IT market amounted to only *** billion U.S. dollars. In 2022, the most valuable segment in Brazil’s IT market was hardware, amounting to **** billion U.S. dollars, while the country’s software market was valued at **** billion U.S. dollars. Brazil’s software market In 2020, the most important segments of Brazil’s software market were software application, software development environment, and infrastructure and security, with the latter accounting for nearly ** percent of the country’s software market. At the same time, the market revenue of Software as a Service (SaaS) increased over the past years, peaking at *** billion U.S. dollars in 2020. This growth spike was almost double the value recorded in 2017. When it comes to regional distribution, over ** percent of Brazil’s software market was concentrated in the South-Eastern region in 2022. By contrast, the Northern part of the country accounted for approximately ***** percent of Brazil’s software market. Software companies in Brazil In 2022, more than ** thousand companies were operating in the Brazilian IT service industry, and approximately ***** thousand companies specialized in software development and production. One of the most important software companies is Totvs, which also operates in the United States, Portugal, and Latin America. In the first semester of 2021, the company generated **** billion Brazilian reals in revenue with their software services. Another software company that operates in Brazil, as well as in several other Latin American countries is Globant. In 2021, Globant’s revenue in Brazil amounted to almost ** million U.S. dollars. By contrast, Globant’s revenue in the U.S. totaled *** million U.S. dollars in the same year.

Global AAV Vector is segmented by Application (Gene therapy, Vaccine delivery, Research, Clinical trials, Cell therapy, Genetic engineering, Drug delivery, Biomanufacturing), Type (Single-stranded, Self-complementary, Recombinant, Wild-type, Serotype 1-9, Modified capsids, Clinical grade, Research grade) and Geography(North America, LATAM, West Europe, Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA)